Clinical course of HCV-associated liver cirrhosis after viral eradication in transplant candidates

Objective: to investigate markers of liver injury ( MELD-Na and Child–Turcotte–Pugh [CTP] scores) before and after treatment with direct-acting antiviral (DAA) therapy, and to characterize clinical outcomes of HCV-associated decompensated liver cirrhosis following viral eradication in liver transplant (LT) candidates. Materials and methods. A prospective comparative study was conducted in 320 patients with decompensated cirrhosis listed for LT. Demographic, clinical, and laboratory parameters were analyzed, including MELD-Na and CTP scores, severity of hepatic encephalopathy, ascites, number of bleeding episodes, and occurrence of complications. Assessments were performed prior to HCV therapy and 12 months after achieving sustained virologic response (SVR). Subgroup analyses included patients who transitioned to compensated cirrhosis (n = 113) and those who remained or progressed to decompensated cirrhosis (n = 207). Cumulative risks were evaluated using Cox proportional hazards regression in univariate and multivariate models. Results. After 12 months of follow-up following the achievement of SVR, significant increases were observed in white blood cell and platelet counts, as well as serum albumin levels. In parallel, creatinine, international normalized ratio (INR), and bilirubin levels decreased. There was also a reduction in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity, along with improvements in the severity of ascites and hepatic encephalopathy, a decrease in the number of bleeding episodes, and lower CTP and MELD-Na scores. Predictors of further decompensation of cirrhosis included decreased serum sodium level, increased severity of liver injury on CT imaging, greater severity of ascites and hepatic encephalopathy, and a higher number of complications during follow-up.

1. Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study. Gastroenterology. 2015; 148: 100– 107.e1. doi: 10.1053/j.gastro.2014.09.023.

2. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub S‑R, Martini S et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol. 2016; 65: 524–531. doi: 10.1016/j.jhep.2016.05.010.

3. Nabatchikova EA, Abdurakhmanov DT, Rozina TP, Nikulkina EN, Tanaschuk EL, Moiseev SV. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience. Clin Res Hepatol Gastroenterol. 2021 Nov; 45 (6): 101714. doi: 10.1016/j.clinre.2021.101714.

4. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM et al. ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373 (27): 2618–2628. doi: 10.1056/NEJMoa1512614.

5. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S et al. HCV Research, UK. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016 Jun; 64 (6): 1224–1231. doi: 10.1016/j.jhep.2016.01.029.

6. Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int. 2019 Jan; 13 (1): 66–74. doi: 10.1007/s12072-018-9914-6.

7. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr et al. SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Gastroenterology. 2015 Sep; 149 (3): 649–659. doi: 10.1053/j.gastro.2015.05.010.

8. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M et al. SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016 Jun; 16 (6): 685–697. doi: 10.1016/S1473-3099(16)00052-9. Erratum in: Lancet Infect Dis. 2016 Jun; 16 (6): 636. doi: 10.1016/S1473-3099(16)30085-8.

9. De Franchis R, Bosch J, Garcia‑Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022 Apr; 76 (4): 959–974. doi: 10.1016/j.jhep.2021.12.022. Erratum in: J Hepatol. 2022 Jul; 77 (1): 271. doi: 10.1016/j.jhep.2022.03.024.

10. Reiberger T, Hofer BS. The Baveno VII concept of cirrhosis recompensation. Dig Liver Dis. 2023 Apr; 55 (4): 431–441. doi: 10.1016/j.dld.2022.12.014.

11. Hui VW, Wong GL, Wong VW, Chan HL, Lai JC, Tse YK et al. Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis. JHEP Rep. 2023 Jun 14; 5 (9): 100814. doi: 10.1016/j.jhepr.2023.100814.

12. Zhang Y, Liu X, Li S, Lin C, Ye Q, Wang Y et al. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria. Hepatol Commun. 2023 Dec 22; 8 (1): e0355. doi: 10.1097/HC9.0000000000000355.

13. Wang Q, Zhao H, Deng Y, Zheng H, Xiang H, Nan Y et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol. 2022 Dec; 77 (6): 1564–1572. doi: 10.1016/j.jhep.2022.07.037.

14. He Z, Wang B, Wu X, Hu Z, Zhang C, Hao Y et al. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding. Hepatol Int. 2023 Dec; 17 (6): 1368–1377. doi: 10.1007/s12072-023-10579-w.

15. Hofer BS, Simbrunner B, Hartl L, Jachs M, Balcar L, Paternostro R et al. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis. Liver Int. 2023 Oct; 43 (10): 2220–2231. doi: 10.1111/liv.15676.

16. Premkumar M, Dhiman RK, Duseja A, Mehtani R, Taneja S, Gupta E et al. Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program. Gastroenterology. 2024 Dec; 167 (7): 1429–1445. doi: 10.1053/j.gastro.2024.08.018.

17. Carrion AF, Khaderi SA, Sussman NL. Model for end-stage liver disease limbo, model for end-stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantation. Liver Transpl. 2016 Mar; 22 (3): 279–280. doi: 10.1002/lt.24383.

18. Semmler G, Lens S, Hidalgo Á, Alonso López S, Perez-Perez M, Dajti E et al. HCV Recompensation Study Group. Incidence and Clinical Significance of Recompensation After HCV Cure. Clin Gastroenterol Hepatol. 2025 May 14: S1542-3565(25)00414-8. doi: 10.1016/j.cgh.2025.04.026.

19. De Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015; 63: 743–752. doi: 10.1016/j.jhep.2015.05.022.

20. Esophageal varices: World Gastroenterology Organization guidelines. Available from: https://www.worldgastroenterology.org/UserFiles/file/guidelines/esophageal-varices-russian-2014.pdf.

21. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003; 38 (1): 258–266. doi: 10.1053/jhep.2003.50315.

22. Gantzel RH, Aagaard NK, Vilstrup H, Watson H, Grønbaek H, Jepsen P. Development and validation of the Cirrhotic Ascites Severity model-A patient-reported outcome-based model to predict 1-year mortality. Hepatol Commun. 2022 Nov; 6 (11): 3175–3185. doi: 10.1002/hep4.2065.

23. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014; 60 (2): 715–735. doi: 10.1002/hep.27210.

24. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018 Aug; 69 (2): 461–511. doi: 10.1016/j.jhep.2018.03.026.

25. Sharashova ЕЕ, Kholmatova КК, Gorbatova МА, Grjibovski АМ. Cox regression in health sciences using SPSS software. Nauka i zdravookhranenie [Science & Healthcare]. 2017; 6: 5–27.

26. Hosmer JR. DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time‐to‐Event Data, Second Edition. New York: John Wiley & Sons, 2008. doi: 9780470258019.fmatter.

27. Nabatchikova EA, Abdurakhmanov DT, Rozina TP, Tanashchuk EL, Nikulkina EN, Nikiforova NV, Odintsov AV. Improvement of liver function in patients with decompensated liver cirrhosis after hepatitis C virus elimination. Сlinical pharmacology and therapy. 2019; 28 (2): 34–38. [In Russ, English abstract]. doi: 10.32756/0869-5490-2019-2-34-38.

28. El‑Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A et al. Baseline Factors Associated with Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018; doi: 10.1053/j.gastro.2018.03.022.

29. Sánchez‑Torrijos Y, Fernández‑Álvarez P, Rosales JM, Pérez‑Estrada C, Alañón‑Martínez P, Rodríguez‑Perálvarez M et al. Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C. J Hepatol. 2025 Sep; 83 (3): 652–661. doi: 10.1016/j.jhep.2025.02.041.

30. Pearlman BL. Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis. Dig Dis Sci. 2024 May; 69 (5): 1551–1561. doi: 10.1007/s10620-024-08393-x.

31. Meunier L, Belkacemi M, Pageaux GP, Radenne S, Vallet‑Pichard A, Houssel‑Debry P et al. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years? Viruses. 2022 Dec 31; 15 (1): 137. doi: 10.3390/v15010137.

32. Krassenburg LAP, Maan R, Ramji A, Manns MP, Cornberg M, Wedemeyer H et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021 May; 74 (5): 1053–1063. doi: 10.1016/j.jhep.2020.11.021.

33. Van Velsen LM, Krassenburg LAP, Hirode G, Agarwal K, Foster GR, Cargill Z et al. Association Between Sustained Virological Response and Adverse Liver-related Events in Patients with Decompensated Hepatitis C Virus Cirrhosis. Clin Gastroenterol Hepatol. 2025 Sep 15: S1542-3565(25)00796-7. doi: 10.1016/j.cgh.2025.09.006.